Home/Filings/3/0001104659-25-095033
3//SEC Filing

Jeremy M. Sclar 2012 Irrevocable Family Trust 3

Accession 0001104659-25-095033

CIK 0001374339other

Filed

Sep 29, 8:00 PM ET

Accepted

Sep 30, 4:15 PM ET

Size

13.0 KB

Accession

0001104659-25-095033

Insider Transaction Report

Form 3
Period: 2024-10-23
Holdings
  • Warrants to Purchase Common Shares, no par value

    From: 2023-04-11Exp: 2028-04-11Common Shares (26,217 underlying)
  • Tranche A Common Share Purchase Warrants

    From: 2024-10-23Common Shares (697,674 underlying)
  • Common Stock, no par value

    1,617,437
  • Warrants to Purchase Common Shares, no par value

    From: 2024-02-24Exp: 2029-02-24Common Shares (664,894 underlying)
  • Tranche B Common Share Purchase Warrants

    From: 2024-10-23Common Shares (697,674 underlying)
  • Tranche C Common Share Purchase Warrants

    From: 2024-07-31Common Shares (697,674 underlying)
Footnotes (6)
  • [F1]Consists of 26,217 warrants to purchase Common Shares, each exercisable to purchase one Common Share at an exercise price of $7.50 per whole warrant. These warrants are part of Units acquired on October 11, 2022, each consisting of one Common Share and one-quarter of one warrant to purchase one Common Share. The purchase price for each Unit was $5.40. These warrants are currently exercisable and expire on April 11, 2028, the fifth anniversary of the date the warrants first became exercisable.
  • [F2]Consists of 664,894 warrants to purchase Common Shares, each exercisable to purchase one Common Share at an exercise price of $1.75 per share. These warrants are part of Units acquired on August 24, 2023, each consisting of one Common Share and one warrant to purchase one Common Share. The purchase price for each Unit was $1.88. These warrants are currently exercisable and expire on February 24, 2029, the fifth anniversary of the date the warrants first became exercisable.
  • [F3]On July 31, 2024, the Reporting Person acquired 697,674 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit.
  • [F4]Consists of 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants became immediately exercisable beginning on the date that approval as was required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche A purchase warrants and the Common Shares upon the exercise thereof was received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 18 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.
  • [F5]Consists of 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants became exercisable beginning on the date that such approval as was required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche B purchase warrants and the Common Shares upon the exercise thereof was received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 30 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.
  • [F6]Consists of 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.50 per warrant share. These warrants became exercisable when acquired on July 31, 2024 and expire on July 31, 2029.

Issuer

ProMIS Neurosciences Inc.

CIK 0001374339

Entity typeother
IncorporatedMA

Related Parties

1
  • filerCIK 0002089163

Filing Metadata

Form type
3
Filed
Sep 29, 8:00 PM ET
Accepted
Sep 30, 4:15 PM ET
Size
13.0 KB